Profile data is unavailable for this security.
About the company
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. The Company's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). Its oncology product candidate, KZR-261, is a small molecule agent, targeting the Sec61 translocon and protein secretion pathway, being studied in an open-label Phase I clinical trial designed to evaluate safety and tolerability, pharmacokinetics and pharmacodynamics, as well to explore preliminary anti-tumor activity. This study is being conducted in two parts: dose escalation in patients with locally advanced or metastatic solid malignancies, and dose expansion in patients with selected tumor types.
- Revenue in USD (TTM)7.00m
- Net income in USD-101.87m
- Incorporated2015
- Employees58.00
- LocationKezar Life Sciences Inc4000 Shoreline Ct Ste 300SOUTH SAN FRANCISCO 94080-2005United StatesUSA
- Phone+1 (650) 822-5600
- Fax+1 (302) 636-5454
- Websitehttps://kezarlifesciences.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vaxxinity Inc | 0.00 | -56.94m | 43.23m | 57.00 | -- | 3.22 | -- | -- | -0.4499 | -0.4499 | 0.00 | 0.1058 | 0.00 | -- | -- | 0.00 | -75.56 | -- | -111.46 | -- | -- | -- | -- | -- | -- | -- | 0.5308 | -- | -- | -- | 24.31 | -- | -- | -- |
| Dare Bioscience Inc | 2.82m | -28.87m | 43.60m | 23.00 | -- | -- | -- | 15.48 | -0.3175 | -0.3175 | 0.0308 | -0.1094 | 0.1299 | -- | 1.49 | 122,486.50 | -133.12 | -109.51 | -4,386.38 | -246.26 | 0.0579 | -- | -1,024.93 | -1,104.55 | -- | -- | -- | -- | -71.92 | -- | 2.54 | -- | 121.37 | -- |
| Inotiv Inc | 552.74m | -71.29m | 43.89m | 1.96k | -- | 0.2113 | -- | 0.0794 | -2.77 | -2.77 | 21.44 | 8.00 | 0.6565 | 7.18 | 7.91 | 282,733.50 | -8.58 | -23.84 | -13.63 | -29.26 | 28.76 | 29.31 | -13.07 | -33.24 | 0.2744 | -0.1734 | 0.6476 | -- | 4.52 | 85.10 | 68.80 | -- | 83.64 | -- |
| Curis Inc | 9.81m | -47.73m | 44.21m | 48.00 | -- | 4.67 | -- | 4.51 | -8.68 | -8.68 | 1.77 | 1.61 | 0.1253 | -- | 4.39 | 204,416.70 | -60.97 | -37.25 | -69.58 | -41.12 | 97.60 | 96.05 | -486.45 | -409.44 | -- | -- | 0.00 | -- | -1.37 | -0.7891 | 16.34 | -- | -- | -- |
| NextCure Inc | 0.00 | -63.73m | 44.76m | 82.00 | -- | 0.4508 | -- | -- | -2.29 | -2.29 | 0.00 | 3.55 | 0.00 | -- | -- | 0.00 | -45.05 | -22.59 | -47.72 | -23.54 | -- | -- | -- | -964.96 | -- | -- | 0.00 | -- | -- | -- | 16.07 | -- | -23.17 | -- |
| Clene Inc. | 620.00k | -48.81m | 45.09m | 82.00 | -- | 10.58 | -- | 72.73 | -0.4764 | -0.4764 | 0.0053 | 0.0332 | 0.0146 | 2.11 | 9.76 | 7,560.98 | -114.91 | -39.43 | -233.02 | -47.32 | 78.71 | -- | -7,873.23 | -5,261.20 | 1.22 | -32.64 | 0.8641 | -- | 38.27 | -- | -65.47 | -- | -- | -- |
| Lantern Pharma Inc | 0.00 | -17.53m | 45.94m | 21.00 | -- | 1.28 | -- | -- | -1.62 | -1.62 | 0.00 | 3.32 | 0.00 | -- | -- | 0.00 | -36.82 | -28.83 | -39.63 | -30.17 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.93 | -- | -- | -- |
| Kezar Life Sciences Inc | 7.00m | -101.87m | 45.94m | 58.00 | -- | 0.2449 | -- | 6.56 | -1.40 | -1.40 | 0.0965 | 2.58 | 0.0269 | -- | -- | 120,689.70 | -39.12 | -32.54 | -41.41 | -34.09 | -- | -- | -1,455.29 | -4,308.11 | -- | -- | 0.051 | -- | -- | -- | -49.28 | -- | 10.08 | -- |
| ANEW Medical Inc | 0.00 | 102.30k | 46.05m | -- | 740.29 | 1.69 | 450.19 | -- | 0.0049 | 0.0049 | 0.00 | 2.15 | 0.00 | -- | -- | -- | 0.1468 | -- | 0.2833 | -- | -- | -- | -- | -- | -- | -- | 0.1454 | -- | -- | -- | 9.14 | -- | -- | -- |
| Moolec Science SA | 2.90m | -6.48m | 46.81m | 45.00 | -- | 6.15 | -- | 16.16 | -0.2079 | -0.2079 | 0.0838 | 0.1779 | 0.1302 | -- | 4.81 | 64,382.45 | -29.13 | -- | -51.98 | -- | 10.67 | -- | -223.70 | -- | 0.3681 | -9.90 | 0.555 | -- | -- | -- | -1,044.02 | -- | -- | -- |
| Ocean Biomedical Holdings Inc | 0.00 | -45.58m | 47.47m | 9.00 | -- | -- | -- | -- | -1.40 | -1.40 | 0.00 | -0.0642 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -612.50 | -- | -- | -- |
| Tempest Therapeutics Inc | 0.00 | -29.76m | 47.99m | 17.00 | -- | 2.33 | -- | -- | -1.76 | -1.76 | 0.00 | 0.9287 | 0.00 | -- | -- | 0.00 | -72.84 | -57.10 | -93.72 | -71.20 | -- | -- | -- | -- | -- | -141.39 | 0.3394 | -- | -- | -- | 17.41 | -- | 36.40 | -- |
| CASI Pharmaceuticals Inc | 28.94m | -30.48m | 48.05m | 176.00 | -- | 3.11 | -- | 1.66 | -2.28 | -2.28 | 2.16 | 1.15 | 0.3954 | 1.00 | 3.41 | 164,437.50 | -40.88 | -34.75 | -59.15 | -46.91 | 58.36 | 55.98 | -103.40 | -153.72 | 3.25 | -76.70 | 0.5458 | -- | -21.41 | -- | 34.27 | -- | 14.65 | -- |
| Regencell Bioscience Holdings Ltd | 0.00 | -4.71m | 48.41m | 12.00 | -- | 4.76 | -- | -- | -0.362 | -0.362 | 0.00 | 0.781 | 0.00 | -- | -- | 0.00 | -37.91 | -- | -37.91 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.15 | -- | -- | -- |
| LAVA Therapeutics NV | 12.54m | -28.59m | 48.63m | 37.00 | -- | 0.9599 | -- | 3.88 | -1.07 | -1.07 | 0.4668 | 1.93 | 0.107 | -- | 9.09 | 338,837.80 | -24.40 | -- | -28.91 | -- | 79.64 | -- | -228.02 | -- | -- | -- | 0.108 | -- | -65.09 | -- | -31.55 | -- | -- | -- |
Data as of Jun 28 2024. Currency figures normalised to Kezar Life Sciences Inc's reporting currency: US Dollar USD
39.88%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Suvretta Capital Management LLCas of 31 Mar 2024 | 7.17m | 9.85% |
| Avidity Partners Management LPas of 31 Mar 2024 | 5.03m | 6.90% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 4.17m | 5.73% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 3.05m | 4.18% |
| Sphera Funds Management Ltd.as of 31 Mar 2024 | 2.05m | 2.82% |
| Acadian Asset Management LLCas of 31 Mar 2024 | 1.79m | 2.46% |
| Affinity Asset Advisors LLCas of 31 Mar 2024 | 1.76m | 2.42% |
| Geode Capital Management LLCas of 31 Mar 2024 | 1.37m | 1.89% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 1.34m | 1.84% |
| Two Sigma Investments LPas of 31 Mar 2024 | 1.30m | 1.79% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
